Peter W. Collins

Heath Park
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 01, 2009

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: October 13, 2009

Advances in the understanding of acquired haemophilia A: implications for clinical practice.

Advances in the understanding of acquired haemophilia A: implications for clinical practice.

Journal: British journal of haematology

Published: October 10, 2009

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 27, 2009

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 16, 2009

Type 1 von Willebrand disease: application of emerging data to clinical practice.

Type 1 von Willebrand disease: application of emerging data to clinical practice.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: May 31, 2008

Treatment of acquired hemophilia A.

Treatment of acquired hemophilia A.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 28, 2007

Inhibitors, what is the risk of treatment intensity?

Inhibitors, what is the risk of treatment intensity?

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 21, 2007

Novel therapies for immune tolerance in haemophilia A.

Novel therapies for immune tolerance in haemophilia A.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: November 25, 2006

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Journal: Blood

Published: October 19, 2006

A population based, unselected, consecutive cohort of patients with acquired haemophilia A.

A population based, unselected, consecutive cohort of patients with acquired haemophilia A.

Journal: British journal of haematology

Published: December 17, 2003

Showing 1-11 of 11

Last Updated: 09/26/2026